Investigation of computed tomography findings of portal hypertension at non-alcoholic fatty liver disease

被引:0
|
作者
Kulali, Fatma [1 ]
Kaya-Tuna, Burcu [1 ]
Semiz-Oysu, Aslihan [1 ]
Kilicoglu, Zeynep Gamze [2 ]
Bukte, Yasar [1 ]
机构
[1] Umraniye Training & Res Hosp, Istanbul, Turkey
[2] Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey
关键词
Hepatosteatosis; Portal hypertension; Fatty liver; Cirrhosis;
D O I
10.1016/j.ejrnm.2016.05.012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is very common and serious disease. It begins as a simple hepatosteatosis but can progress to cirrhosis. The early detection of portal hypertension (HT) can be helpful in the management of these patients. Aims: To evaluate radiologic findings of portal hypertension at computed tomography (CT) of patients with non-alcoholic fatty liver disease for early diagnosis. Methods and materials: Images of 225 cases who underwent non-enhanced abdominal CT were reviewed. The patients with the difference between hepatic and splenic attenuation (CT L-S) > 10 were enrolled in hepatosteatosis group. The remainings formed control group. The relationship between two groups about diameters of portal and splenic veins, craniocaudal (CC) span of liver, splenic index, caudate lobe/right lobe (C/RL) ratio was analyzed statistically by Mann-Whitney U Test and Student's t-test. Results: Total 213 cases, as hepatosteatosis (n = 149) and control (n = 64) groups, were involved in this study. Liver CC span, splenic index and C/RL ratio between two groups were found to be statistically significant (p < 0.01). Conclusions: The splenic index and C/RL ratio are important findings of portal HT and fibrosis. CT imaging can be beneficial for diagnosis and treatment of NAFLD patients. (C) 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
引用
收藏
页码:707 / 710
页数:4
相关论文
共 50 条
  • [41] Inherited susceptibility to non-alcoholic fatty liver disease
    R. J. F. Loos
    D. B. Savage
    Diabetologia, 2009, 52 : 1000 - 1002
  • [42] Hepatocellular carcinoma and non-alcoholic fatty liver disease
    Golabi, Pegah
    Rhea, Logan
    Henry, Linda
    Younossi, Zobair M.
    HEPATOLOGY INTERNATIONAL, 2019, 13 (06) : 688 - 694
  • [43] Clinical approaches to non-alcoholic fatty liver disease
    Katherine JP Schwenger
    Johane P Allard
    World Journal of Gastroenterology, 2014, (07) : 1712 - 1723
  • [44] Helicobacter pylori and non-alcoholic fatty liver disease
    Buzas, Gyorgy M.
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2020, 66 (03) : 267 - 279
  • [45] The Natural Course of Non-Alcoholic Fatty Liver Disease
    Bertot, Luis Calzadilla
    Adams, Leon Anton
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (05)
  • [46] Clinical approaches to non-alcoholic fatty liver disease
    Schwenger, Katherine J. P.
    Allard, Johane P.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (07) : 1712 - 1723
  • [47] Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease
    Mitten, Emilie K.
    Baffy, Gyorgy
    JOURNAL OF HEPATOLOGY, 2022, 77 (06) : 1642 - 1656
  • [48] Inherited susceptibility to non-alcoholic fatty liver disease
    Loos, R. J. F.
    Savage, D. B.
    DIABETOLOGIA, 2009, 52 (06) : 1000 - 1002
  • [49] The natural course of non-alcoholic fatty liver disease
    Seval, Guldane Cengiz
    Kabacam, Gokhan
    Yakut, Mustafa
    Seven, Gulseren
    Savas, Berna
    Elhan, Atilla
    Cinar, Kubilay
    Idilman, Ramazan
    HEPATOLOGY FORUM, 2020, 1 (01): : 20 - 24
  • [50] Future therapy for non-alcoholic fatty liver disease
    Issa, Danny
    Patel, Vaishali
    Sanyal, Arun J.
    LIVER INTERNATIONAL, 2018, 38 : 56 - 63